Oskira-2: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To Disease-Modifying Antirheumatic Drugs. Dawes, P., Dimic, A., Genovese, M. C., van der Heijde, D., Jenkins, M., O'Brien, C., Oemar, B., Vencovsky, J., Weinblatt, M. WILEY-BLACKWELL. 2013: S198–S199

View details for Web of Science ID 000325359201454